Short courses of high-dose inhaled budesonide and serum IgG subclass levels in healthy volunteers.
BACKGROUND
The incidence of systemic side effects of inhaled budesonide increases at doses exceeding 2000 micrograms/day.


OBJECTIVE
This study was carried out to investigate whether high-dose inhaled budesonide affects serum IgG subclass concentrations in healthy adult volunteers.


METHODS
Two groups of 10 subjects each inhaled 2.4 mg of budesonide per day in a double-blind, crossover study of morning (8:00 AM and noon, group A) and diurnal (8:00 AM and 8:00 PM, group B) dosing schedules for 4 weeks each, separated by a 2-week washout period. The budesonide was inhaled through a pressurized metered-dose inhaler, mounted on a 750 ml Nebuhaler (ASTRA Pharmaceuticals, Lund, Sweden). The IgG subclass levels were determined at baseline and every 2 weeks until the end of the study period (10 weeks).


RESULTS
There were no statistically significant changes in the serum IgG subclass concentrations over the 10-week study period in group A, group B, or groups A and B combined.


CONCLUSIONS
Inhalation of budesonide, 2.4 mg/day, through a large-volume spacer for repeated 1-month periods does not influence serum IgG subclass concentrations in healthy adults, suggesting that budesonide does not cause systemic humoral immunosuppression when given at therapeutic doses.
Van Schoor
J
J
Department of Respiratory Diseases, University Hospital, Ghent, Belgium.
Toogood
J H
JH
Pauwels
R A
RA
D000280:Administration, Inhalation; D000287:Administration, Topical; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000276:immunology*; D019819:Budesonide; D005938:Glucocorticoids; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D011282:Pregnenediones / Q000008:administration & dosage / Q000276:immunology*
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D007074:Immunoglobulin G; D011282:Pregnenediones; D019819:Budesonide